DIA 3rd Cardiac Safety Workshop Explores the Future of the TQT Study And Issues Surrounding the Conduct and Analysis of TQT Studies in Japan

Posted:
9
May 2012

Dr J�rg T�ubel, will be presenting again at the DIA 3rd Cardiac Safety Workshop in Japan, taking place in Tokyo from 28-29 May 2012.The 3rd Cardiac Safety Workshop in Japan will explore topics surrounding the future of the TQT study, including the emerging intensive QT studies, the use of positive controls for assay sensitivity, the risks involved in TQT studies, as well as other issues specific to Japan. The meeting will bring together experts and members of academia, regulatory and drug development organisations for 2 days of intensive discussion, debates and updates.Dr Taubel's extensive experience in investigating ethnic differences and bridging ECG studies exploring physiological and drug induced effects makes him a world leading expert in the evaluation of effects of ethnicity on the ECG. His recent work includes studies in both Caucasian and Japanese participants using techniques such as an euglycaemic insulin clamp investigating the effects of food on the QT interval in a proper ICH E14 setting. He will present some of his latest data.Click here to view the full programWe invite you to be a part of this hugely informative event on current issues facing the industry and network with like-minded scientific professionals. A Business Development representative from Richmond Pharmacology will also be standing by for the duration of the workshop to discuss your prospective TQT study requirements and how we can benefit towards its total success.To arrange a face to face meeting or request a copy of our latest TQT publication,contact a member of our BD Team today.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more